- Global Pharma News & Resources

BiondVax CEO to Present at 'World Vaccine Congress 2018 San Diego' About BiondVax's Phase 3 Universal Flu Vaccine Candidate

BiondVax CEO to Present at 'World Vaccine Congress 2018 San Diego' About BiondVax's Phase 3 Universal Flu Vaccine Candidate

PR Newswire

JERUSALEM, Nov. 26, 2018

JERUSALEM, Nov. 26, 2018 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), developer of the M-001 universal influenza vaccine candidate, reported today it will present this week at the World Vaccine & Immunotherapy Congress West Coast 2018 in San Diego.

Dr. Ron Babecoff, BiondVax's Founder and CEO, will participate in a panel discussion and provide an overview of the Company's achievements and plans, including the ongoing pivotal, clinical efficacy, Phase 3 trial.

Details of Dr. Babecoff presentations:

  1. Panel: How will we integrate knowledge gained from the UIVI and other research into the development of a Universal Influenza Vaccine?
    Date: Wednesday, November 28, 2018
    Time: 12:35pm
  2. Getting Closer to the Market: BiondVax's Universal Flu Vaccine Pivotal Phase 3 Trial
    Date: Wednesday, November 28, 2018
    Time: 3:50pm

Those interested in meeting with Dr. Babecoff are invited to contact Joshua Phillipson at

About BiondVax

BiondVax (NASDAQ: BVXV) is a Phase 3 clinical stage biopharmaceutical company developing a universal flu vaccine. The vaccine candidate, called M-001, is designed to provide multi-season protection against current and future, seasonal and pandemic influenza virus strains. BiondVax's proprietary technology utilizes a unique combination of conserved and common influenza virus peptides, activating both arms of the immune system for a cross-protecting and long-lasting effect. In a total of 6 completed Phase 1/2 and Phase 2 human clinical trials, covering 698 participants, the vaccine has been shown to be safe, well-tolerated, and immunogenic. Please visit

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Litigation Reform Act of 1995. Words such as "expect," "believe," "intend," "plan," "continue," "may," "will," "anticipate," and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve certain risks and uncertainties reflect the management's current views with respect to certain current and future events and are subject to various risks, uncertainties and assumptions that could cause the results to differ materially from those expected by the management of BiondVax Pharmaceuticals Ltd. Risks and uncertainties include, but are not limited to, the prosecution and outcome of the ongoing Phase 2 and Phase 3 trials and any subsequent trials; timing of receipt of regulatory approval of the new manufacturing facility its products; ability to demonstrate the efficacy and safety of the vaccine; the timing of clinical trials and marketing approvals; the risk that drug development involves a lengthy and expensive process with uncertain outcome; the ability of the Company to maintain, preserve and defend its intellectual property and patents granted; whether our  vaccine candidate will successfully advance through the clinical trial process on a timely basis, or at all, and receive approval from the United States Food and Drug Administration or equivalent foreign regulatory agencies; the adequacy of available cash resources and the ability to raise capital when needed. More detailed information about the risks and uncertainties affecting the Company is contained under the heading "Risk Factors" in our Annual Report on Form 20-F for the year ended December 31, 2017 filed with the U.S. Securities and Exchange Commission, or SEC, which is available on the SEC's website,, and in the Company's periodic filings with the SEC. We undertake no obligation to revise or update any forward-looking statement for any reason.

Contact Details
Joshua E. Phillipson | +972-8-930-2529 |

View original content to download multimedia:

SOURCE Biondvax Pharmaceuticals Ltd

Editor Details

Last Updated: 26-Nov-2018